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Chapter 1: Introduction
1.1 HIV-1 Viral Infection
According to estimates by the CDC, as of 2011 there were more than 1.2 million people living
with HIV in the United States. The risk of HIV infection continues to be a serious public health
concern; over the past two decades, incidence of HIV infection has stabilized at approximately
50,000 new infections per year in the US. Of those infected, men who have sex with men (MSM),
African Americans and those of Latin American descent, are disproportionately affected. In the
rest of the world, HIV infection also remains an issue, with about 2.1 million new cases of HIV
being reported in 2013. There are an estimated 35 million people living with HIV around the
world,

with

sub-Saharan

Africa

most

heavily

affected

by

the

disease

[CDC.gov/HIV/statistics/overview].

1.2 HIV-1 Protease
HIV-1 protease (PR) is a 99 amino acid homo-dimeric enzyme. The two monomers of the PR
form a central active site channel which contains the catalytic residues Asp 25 and Asp 25’. HIV
PR is responsible for the maturation of virions by cleaving the Gag and GagPol polyprotein
precursors into functionally active proteins [1][2]. The Gag precursor is cleaved into the structural
proteins including the matrix, capsid, nucleocapsid, and spacer peptides p1, and p2. The Pol
precursor is cleaved into the viral enzymes protease, reverse transcriptase and integrase [1]. As
HIV-1 PR plays such an essential role in the HIV-1 viral life cycle, it has become an attractive and
successful target for drug development.
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1.3 HIV-1 PR Inhibitors
To combat HIV infection, highly active anti-retroviral therapy (HAART) remains the standard
of care, with protease inhibitors (PIs) playing an essential role. HAART typically consists of a
cocktail of anti-retroviral drugs including two nucleoside reverse transcriptase inhibitors (NRTIs),
along with either a non-nucleoside reverse transcriptase inhibitory (NNRTI) or a PI. HAART
combinations including PIs have been typically more effective than combinations that do not
include PIs, and monotherapies [3].
There are currently nine PIs approved for use by the FDA: Ritonavir (RTV), Lopinavir (LPV),
Atazanavir (ATV), Darunavir (DRV), Saquinavir (SQV), Indinavir (IDV), Nelfinavir (NFV),
Tipranavir (TPV) and Fosamprenavir (FPV). PIs inhibit PR by binding to the active site residues,
competing with the natural substrate peptides. PIs have been designed to mimic the natural
transition state of the peptide, where the PI hydroxyl interacts with the carbonyl of Asp 25 and
Asp 25’ in the HIV PR active site, thus inactivating the enzyme [4]. Unfortunately, drug resistance
PR mutations have been associated with each PI. Because of their similar structure, and mechanism
of action, it is common for cross resistance to occur between PIs , resulting in treatment failure
[4][5]. Mutations in regions flanking the binding pocket of HIV-1 protease are typically seen in PI
resistance, because in this area the mutations will interfere with inhibitor binding but not Gag and
GagPol binding [6].
1.4 HIV-1 PR and Drug Resistance
Though PIs have been effective at reducing HIV related deaths, resistance to these drugs occurs
when mutations in the PR lead to reduced binding affinity of the PR for the inhibitor, while
interactions between the PR and substrate remain [7]. Thus, inhibitors are unable to bind and block
enzyme activity, while substrate continues to bind and be cleaved by the PR.
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Mutations which lead to PI resistance occur in large part due to the highly error prone reverse
transcriptase and its lack of proof reading ability. As PR mutations accumulate in the viral
population, there is an increase in genetic diversity; an evolutionary advantage for the virus which
under drug induced selective pressure allows for PR with these mutations to proliferate if they
confer a survival advantage in the presence of a PI. Non-compliance with HAART therapy can
accelerate the process of selecting drug resistant mutants [5].
These mutations affect drug-PR interactions in a variety of ways, depending on the type of
mutation present. Amino acid substitutions in the PR active site, called primary mutations, account
for the majority of PI resistance and directly alter drug-PR interactions, resulting in the inability
of the drug to bind and efficiently block enzyme function [5][7]. Primary mutations may result in
cross-resistance due to PIs being similar in structure, but they may also reduce the catalytic activity
of the PR as well [7]. Resistance mutations may also occur at the dimer interface disrupting the
interactions between the two monomers. Changes in the interaction network between the two
monomers of PR, could result in dissociation of the dimer and release the PI from the active site
[5]. Mutations distant from the active site have also been shown to confer resistance by altering
interactions indirectly between necessary water molecules, and enzyme dynamics. These distant
mutations may also in some ways modulate the activity of major resistance mutations in ways that
are not immediately apparent [5]. Mutations in the PR are not always substitutions, insertions have
been documented in the literature, though their mechanism of action and the role they play in PI
resistance remains unclear.
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1.5 HIV-1 PR Insertion Mutations
Of all mutations, insertions in the HIV protease remain among the most understudied in the
literature. Protease insertions typically occur as repeating sequences of neighboring amino acids,
and the proposed mechanism by which insertions are formed is thought to be due to slipping of
the reverse transcriptase [8][9]. Insertions occur at many different positions in the HIV protease,
but tend to occur near external loops and turns, especially in larger insertions of more than five
amino acids. Insertions in the PR are thought to be rare, in one study comprising only 0.1% of
mutations in a sample population between 1999-2000 [8]. Insertions themselves are not shown to
have an effect on resistance to PIs. A 2001 study showed that no real difference existed in drug
susceptibility between multi-drug resistant (MDR) isolates containing an insertion, and noninsertion containing isolates [10]. This suggests that the PI resistance mutations (rather than the
insertion) were responsible for decreased susceptibility to PIs [10]. However, some evidence
suggests that insertions may in fact be compensatory to resistance mutations . These data suggest
that MDR proteases containing an insertion show a boost in substrate cleavage, and replicative
capacity [8].
1.6 HIV-1 PR Clinical Isolate
At present, there are no modeling studies of an insert-containing PR isolate. We report a
detailed modelling study of an isolate containing a 5-residue insertion between codons 28 and 29
(MDR/28). This isolate was obtained from a patient at the Wayne State University Infectious
Disease Clinic in Detroit, MI. The patient is poorly adherent with antiretroviral therapy. MDR/28
is the first isolate at this facility to contain an insertion of this size. Additionally, this isolate
displays reduced replicative capacity compared to the WT virus, as it is expected most mutations
will reduce replicative capacity. To structurally characterize the impact of the MDR/28 insertion,
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a homology model was created and compared to a wild-type crystal structure and a protease
model containing the MDR mutations with the insert removed. Each protease model was then
docked with protease inhibitors (PI) and cleavage peptide CA/p2 [11]. Molecular dynamics
simulations were performed for each of the complexes using NAMD [12].
Chapter 2: Materials and Methods
2.1 Phenotypic and Genotypic Reports
Phenotypic reports regarding the mutant MDR/28 PR were obtained from a Phenosense ®
HIV drug resistance test, ordered by the Detroit Medical Center [13]. Phenosense provides a
quantitative measurement of how well the clinical isolate responds to antivirals, including
nucleoside reverse transcriptase inhibitors (NRTIs), nonnucleoside reverse transcriptase inhibitors
(NNRTIs) and protease inhibitors (PIs). This report also includes replicative capacity data.
Viroseq ® HIV-1 genotyping system was used at the Detroit Medical Center in order to
obtain genotypic data on the clinical isolate PR [14]. This system screens against software to
identify known resistance mutations.
2.2 Homology Modeling
A homology model of MDR/28 PR was created using Schrödinger Prime [15]. 2O4S.pdb
was obtained from the Protein Data Bank (rcsb.org) and was used to build the model. 2O4S
exhibits 82% sequence identity to the insertion isolate MDR/28, and was chosen as it provides the
highest sequence homology available for all PR structures in dimer form [16]. A model was created
of MDR PR, with the insertion removed, also using 2O4S.pdb as a template.
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2.3 Molecular Dynamics Simulation
2.3.1 Protease Complex Preparation
Sixteen systems underwent molecular dynamics simulations, including apo structures of
WT HIV-1 PR, MDR/28 PR, and MDR PR, as well as all PR models with ligands bound. The
ligands used for the simulations were DRV, ATV, LPV, SQV, and CA/p2. To obtain proper
coordinates for the ligands, the homology models and WT PR were aligned to pdb entries 4DQV
(DRV) [17], 2NNP (SQV) [18], 3EKY (ATV) [19], 4L1A (LPV) [20], and 3OUD (CA/p2) [21],
using Pymol to obtain proper coordinates [22].
2.3.2 System Preparation
The preparation of the system for MD simulation was carried out using Visual Molecular
Dynamics software (VMD v.1.9.2) [11]. The PR complexes as well as apo structures were placed
in a 12 Å TIP3P water box and were then neutralized with 0.15 M MgCl2. Simulations were
performed for 40 ns using NAMD (e) V 2.9 [23] and CHARMM force field 36 [24] to set
parameters. The Particle Mesh Ewald (PME) method was used to calculate long range coulomb
interactions. Temperature was maintained at 300 K using Langevin dynamics and pressure
maintained at 1 atm using the Nose-Hoover Langevin piston method. All simulations were run
using one of two different computing clusters, the Wayne State University Grid
(www.grid.wayne.edu)

or

Stampede

at

the

Texas

Advanced

Computing

Center

(http://www.tacc.utexas.edu).
2.4. Structural Analysis
Distance measurements and secondary structural analysis were carried out using VMD
[11]. Analysis of the PR active site volume was carried out using Caver analyst, to visualize and
measure the active site channel over the 40ns trajectory [25]. The volume of each tunnel was
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averaged for the whole simulation. To study the interactions between the PR and peptide, Ligplot+
was used to visualize hydrogen bonds and VdW interactions [26]. These too were averaged for
each PR complex over the length of the MD trajectory.
2.5 Docking and Affinity Estimation
In order to quantify a difference in binding affinity between the WT PR and mutant
MDR/28, MM-GBSA calculations were performed using the Prime function of Schrodinger
software [27]. MM-GBSA method calculates the free energy of binding through the use of
molecular mechanics and implicit solvation models, where the binding energy=∆E(complex)- ∆E
(ligand)-∆E(substrate). [27]. In preparation for MM-GBSA analysis, the WT, MDR/28 and MDR
PR and ligands were prepared using the protein preparation wizard and ligprep functions
(Schrodinger release 2014) [28], respectively. Subsequently, induced fit docking with Glide was
performed to accommodate various ligands in each PR active site [29]. The resulting Glide poses
were used as input for the MM-GBSA affinity estimation, and their energy scores were averaged
for each ligand.

Chapter 3: Results
3.1 MDR/28 HIV PR mutant exhibits resistance to multiple protease inhibitors and
displays reduced replicative capacity
Phenosense® susceptibility testing of MDR/28 revealed full or partial resistance to the
following PIs: atazanavir (ATV/r), amprenavir (AMP/r), indinavir (IDV/r), tipranavir (TPV), and
nelfinavir (NFV) (Table 1). It was also determined in a Phenosense® replicative capacity assay
that in the absence of inhibitors the isolate MDR/28 functioned at a reduced replicative capacity
compared to WT (Fig 2).
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Genotyping with Viroseq® showed MDR/28 contained resistance mutations impacting
the affinity of the PIs IDV, LPV, fosamprenavir (FPV), as well as conferring possible resistance
to TPV, DRV, and ATV. Saquinavir (SQV) was the only inhibitor for which there were no
known resistance mutations present (Table 1). A list of resistance mutations found in MDR/28
and their contributions are listed in Fig 1.b.

Table 1: Phenotypic and genotypic susceptibility data. The phenotypic and genotypic
resistance data provided by Phenosense and Viroseq reports are summarized in
the table above. For detailed genotypic information see the resistance mutation key
for MDR/28 in Fig 1.

3.1.1 Discussion
Phenotype and genotype testing revealed that the clinical HIV-1 PR isolate was multidrug resistant (MDR) and contained a five residue insertion at position 28 of the HIV-1 PR gene.
Comparison between phenotypic and genotypic data showed that though the two assays
agreed relatively well, there were some drugs for which the phenotypic and genotypic
resistance data differed (Table 1). For our purposes, we used the phenotypic results in order to
choose drugs to complex with our PR models. Genotypic reports tend to be more predictive of
future drug resistance, as they detect mutations which may only cause resistance if
accompanied by other mutations that modulate their activity. We are interested in the clinical
outcome [i.e. the phenotypic data]. We determined that DRV, ATV, and LPV were the PIs most
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clinically relevant at the current time and as such were chosen for simulation. SQV was used as
well as it is the only PI that MDR/28 was shown to be susceptible to in both assays.

1.a.
(1)PQITLWQRPVVTIKVGGKLKEALLDTGADDTILDDTILEEMDLPGRWKPKIIGGIGGFLRVRQYDQIPIEICG
HKVIGTVVVGPTPMNIIGRNLLTQLGCTLNF(104)

1.b.
Mutation
L10V
V32I
M46I
I54L
A71V
L76V
V82M

Requires additional mutation

Possible
resistance
TPV,IDV,SQV,DRV,ATV,NFV,FPV LPV
TPV,IDV,LPV,DRV,ATV,NFV,FPV
TPV, IDV,LPV,ATV,FPV
NFV
IDV,SQV,LPV,DRV,ATV
NFV
TPV,IDV,SQV,LPV,ATV
DRV
IDV,LPV
TPV,IDV,LPV,ATV,NFV,FPV

Resistance

Resistance
countered

FPV
FPV

TPV

Fig 1. Sequence of the MDR/28 isolate and resistance mutations. (a): The amino acid sequence for
MDR/28 PR is shown above, with the insertion residues colored in purple. The MDR mutations are
colored in red. (b): The genotype of MDR/28 clinical isolate is summarized below according to the
Viroseq HIV-1 genotyping system report.
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Fig 2. Viral replicative capacity of MDR/28. The replicative capacity of MDR/28
mutant virus is shown as compared to a WT virus. MDR/28 displayed an average
replicative capacity of only 29% of WT.

3.2 The active site volume of MDR/28 is increased compared to wild type
The active site channel of MDR/28 initially appeared to be smaller in volume than WT PR
(Fig 3.a). To confirm this observation, Caver analyst was used to compute the length and
bottleneck radius of the active site channel of each PR over the course of the simulation, showing
that in fact MDR/28 active site volume increases as the simulation progresses [25](Fig 3.b). From
this, we calculated the average total volume of each channel, MDR/28 was shown to have a greater
active site channel volume than WT PR by about 16%, contrary to our initial observation (Fig 3.c).
The solvent accessible surface area (SASA) of the catalytic residues Asp 25 and Asp 25’
was measured using the VMD timeline plugin [11]. The SASA of MDR/28 was observed to be
slightly higher than that of WT by 3 Å2 (Fig 4).
3.2.1 Discussion
Previous studies have shown that an increase in the PR active site volume results in a
weaker binding to substrate, due to the loss of important interactions between the PR and
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substrate [30]. It follows that the increased active site volume of MDR/28 PR when compared to
WT, observed in our analysis, will result in a loss of interactions between active site residue side
chains and substrate.
It is worth noting that the increased active site channel volume was seen as a result of the
MD simulation, wherein one of the flap tips of MDR/28 was observed to curl back on itself. It is
possible that this curling back of the flap may result in the spike seen in active site volume from
the 29th to 32nd ns (Fig 3.b). For this reason, we calculated the SASA, and although there is only
a 3 Å2 increase in the binding site (surface area) of MDR/28, this may be sufficient to disturb
interactions between PR and substrate (Fig 3.c). MDR PR that exhibit only a 3.0 Å2 increased
active site volume have been associated with high level resistance over WT PR [31]. For this
reason, we assert that because MDR/28 displays a predicted expansion of SASA area and active
site volume, these may lead to a loss of important interactions with substrate.
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3.a
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3.b

3.c
Protease
WT
MDR/28

Total Average Volume (Å^3)
340
359

Fig 3. The active site volume of MDR/28 relative to WT. (a): From left MDR/28 PR is shown in cyan,
with its corresponding channel volume colored in blue. On the right WT PR is shown in green with
its channel volume in magenta. The channels were calculated using the caver plugin for Pymol, and
represent the active site volume post energy minimization. (b): The average active site volume over
the course of the 40ns simulation is shown. (c): The total average volume for the active site channels
is presented, this represents the average for all channels over 40ns.
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4.a

4.b
PR

AVG SASA

MDR/28

285

WT

282

Fig 4. Solvent available surface area for catalytic residues. (a) The solvent accessible
surface area is shown over the course of a 40ns simulation for residues Asp 25 and
Asp 25’ of MDR and WT PR. (b) The average SASA for each PR is compared. Values
were determined to be statistically significant by one-way ANOVA p < 0.05.
3.3 Peptide binding to MDR/28 is shifted to one side of the active site
In a superimposed view of MDR/28 and WT PR in complex with the CA/p2 peptide, the
peptide appeared to be displaced in the MDR/28 active site after energy minimization was
completed (Fig 5). To quantify this displacement, the distance between the PRs was measured at
the scissile bond carbon using VMD [11]. MDR/28 had shifted 2.9 Å to one side of the active site
compared to the WT complex.
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Fig 5. Superimposed view of MDR/28 and WT peptides. Above view of superimposed
MDR/28 PR (cyan) and WT (green) PR in complex with peptide CA/p2. The peptide MDR/28
shown in blue is displaced towards one side of the active site when compared to the WT
peptide in magenta. This figure is a representation of frame 21 of the trajectory.

In order to confirm that this displacement of the peptide was consistent over the entire 40ns
MD trajectory, measurements were taken for each of the PR complexes, measuring the distance
from each Asp 25 gamma carbon (for ease of measurement) to the scissile carbonyl carbon of the
peptide over the course of the entire simulation (Fig 6). This analysis revealed that as the
simulation progressed, the peptide in the MDR/28 complex moved further away from Asp 25. The
initial distance was 5.23 A at the beginning of the simulation and increased to 8.74 Å by the end,
averaging 8.60 Å for the whole simulation. In contrast, in the WT complex the CA/p2 peptide was
seen to move from 4.71 Å to 5.54 Å away from Asp 25, averaging only 5.36 Å.

28

Fig 6. Distance measurements between the peptide and catalytic residue. The distance
from the CA/p2 scissile carbonyl to the gamma-carbon of Aspartate 25 over the course of
20,000 frames is shown. MDR/28 in blue, WT in orange. The peptide appears to be moving
increasingly further from the catalytic residue.

3.3.1 Discussion
The migration of the peptide away from catalytic residues that is observed in the MDR/28
complex is a result of missing interactions (to be determined in later analysis) which are needed to
allow peptide to bind in the active site for catalysis. It is known that the recognition and binding
of peptide in the PR active site is largely dependent on the shape and size of the peptide in question
[32]. An increased PR active site may not correctly recognize the peptide thus allowing it to move
out of the active site without being cleaved. There is another structural feature that may account
for a lack of interactions between PR-and peptide: secondary structure.
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3.4 The MDR/28 insertion causes local secondary structural changes
In order to see if any secondary structural changes were induced by the insertion that could
account for lost interactions, Ramachandran analysis was performed for residues 25 through 35.
Residues were chosen that flank the insertion on both sides, omitting the insertion residues
themselves. This analysis revealed that compared to WT PR, MDR/28 shows a marked change in
secondary structure at residues 29 and 30 (Fig 7). At residue 29 a right-handed alpha helix
conformation normally present in WT is changed to a beta sheet conformation in MDR/28. Residue
30 displays the opposite effect, with the normal beta sheet conformation being transiently changed
to alpha helical over the course of the simulation. No other residues which surrounded the insertion
showed a change in secondary structure.
MDR PR, which functioned as a control, showed no change in secondary structure when
compared to WT. This is evidence that the five residue insertion at residue 28 transiently affects
the secondary structure of neighboring residues.
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Fig 7.: Secondary structural analysis of insert flanking residues. Ramachandran plot analysis of
secondary structure for each PR, residues 28-31 are pictured above. The residues were chosen to
analyze changes in PR structure on either side of the insertion sequence, and the insertion itself was
not included. Notice the change in secondary structure from WT to MDR/28 at residues 29 and 30 in
particular.

3.4.1 Discussion
In addition to increased active site volume, the changes in secondary structure at residues 29
and 30 may contribute to the loss of interactions in MDR/28 compared to WT PR. Prior research
illustrates that peptide interactions with PR residues 29 and 30 are responsible for the specificity
of the PR for CA/p2 peptide cleavage site [31]. These residues are also known to make hydrogen
bonds to the backbone of all cleavage peptides and residue 30 is known to contribute to specificity
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by making side chain hydrogen bonds to either Glu or Gln residues present in peptides CA/p2,
p2/NC, and p1/p6 [30]. The changing of secondary structure of these residues could have
implications in reducing the number of interactions between PR and peptide.

3.5 Hydrogen bonds and VdW interactions are lost in MDR/28 compared to WT
To investigate if the previous structural changes (increased active site and secondary
structural changes) contribute to a loss of interactions between the PR and peptide, Ligplot+
analysis was used. Every 4ns throughout the MD simulation, the hydrogen bonds and VdW
interactions were calculated for each PR complex, and the total interactions present at each frame
measured across the whole simulation were averaged. Any interactions which were lost in
MDR/28 compared to WT were noted (Table 2). MDR/28 PR lost a total of four hydrogen bonds
to the peptide, and five VdW interactions which were present in the WT complex.

Hydrogen bonds lost
Asp 30
Gly 48
Gly 49
Ala 28

VdW interactions lost
Val 82
Val 32
Met 46
Arg 8
Asp 29

Table 2. Interactions lost between MDR/28 PR and peptide. The lost interactions of MDR/28
with peptide are shown when compared to WT. Both hydrogen bonds and VdW interactions
were investigated over 40ns.
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3.5.1 Discussion
Of interest among the lost interactions are VdW interactions to residue 29 and hydrogen
bonding to residue 30. As previously stated these two residues are important in peptide recognition
and specificity. The fact that these residues are altered in MDR/28, and interactions are lost to
them is further evidence that the insertion has induced a change in the PR which results in its
inability to bind tightly to substrate. Gly 48 is likewise considered a conserved bond among all PR
and Gagpol interactions, and is also missing in MDR/28. The loss of such important interactions
implies that binding affinity between PR and substrate may be negatively affected in MDR/28, and
thus lead to a reduced replicative capacity.

3.6 MM-GBSA binding affinity data shows MDR/28 has decreased affinity for substrate and
ligands
A loss of interactions between the PR and peptide suggests decreased binding affinity. Data
from MM-GBSA calculations showed that ligands were predicted to bind more tightly to WT PR
than MDR/28 PR (Fig 8). The difference in binding affinity that was observed between MDR/28,
MDR and WT PR was determined to be statistically significant by single factor ANOVA for all
ligands. All PIs and CA/p2 in complex with MDR/28- displayed a decreased binding energy of at
least 26% (for SQV) and up to 36% (for LPV) (compared to WT).
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Fig 8.: Binding affinity data for PR complexes. The normalized binding energy of PR complexes was
determined using the MM-GBSA function of Schrodinger Prime software. The binding energy data is
a normalized average for each complex, as each drug had numerous possible poses in the PR active
site. For each ligand p < 0.05.

3.6.1 Discussion
MM-GBSA analysis predicted MDR/28 has a worse affinity for substrate than WT, as our
previous data had suggested. Interestingly MDR/28 has a better binding affinity than the MDR
control, suggesting that there is a compensatory effect to the insertion. The decrease in binding
affinity of MDR/28 as a result of lost interactions, may result in the displaced peptide and its
subsequent migration from the catalytic residues seen during the 40ns MD simulation.
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Conclusions
Our goal was to elucidate the mechanism of reduced replicative capacity in a mutantbearing PR with an insertion at residue 28. Structural changes in the PR introduced by the insertion
(such as the increased active site volume and secondary structural changes of residues 29 and 30),
resulted in a loss of hydrogen bonds and VdW interactions between the PR active site and the
peptide CA/p2. The loss of necessary contacts leads to decreased affinity of MDR/28 for peptide,
which allows for the displacement of the peptide in the active site and its migration away from the
catalytic residues. Without proper interactions between the PR and peptide, the peptide is unable
to be held in the proper conformation for cleavage, and mature proteins will not result. This could
result in a reduced replicative capacity for the virus. No mechanism of the effect of the insertion
(rather than other MDR mutations) on PIs was seen in the data.
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HIV-1 protease (PR) is a 99 amino acid protein responsible for cleavage of the viral
polyprotein. We have identified a novel clinical isolate, MDR/28, which contains a five residue
insertion between codons 28 and 29 of a multi-drug resistant (MDR) PR. This clinical isolate
displays reduced viral replicative capacity compared to the wild-type. As opposed to drugresistance mutations, studies on insertions remain largely underrepresented in the literature,
and the consequences of such insertions are largely unknown. To understand the mechanism
leading to reduced replicative capacity, three PR models were created and subjected to 40ns
molecular dynamics simulations: MDR/28, wild type, and MDR PR. In addition, PR inhibitors (PI)
atazanavir (ATV), darunavir (DRV), lopinavir (LPV) and saquinavir (SQV), as well as cleavage
peptide CA/p2 were docked to the three models. The MDR/28-PI complexes displayed decreased
binding affinity when compared to WT complexes, likely due to an increased active site cavity
volume and altered secondary structure at residues local to the insertion mutant. Additionally,
in the active site of MDR/28 the predicted binding mode of the CA/p2 peptide did not include
contact with the catalytic residues, and migrated from that position, a behavior not
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seen with any tested PIs or with either of the other PR models. These structural changes
produced by the insertion suggest a mechanism for reduced replicative capacity of the mutant
virus.
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